ImageneBio, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 81.7K | $408.48K | 0.00% | Added+23.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-07 | -0.66 | -0.95 | -43.94% |
| 2025-11-12 | -1.00 | -2.91 | -191.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| IMA | +3.89% | -3.76% | -14.78% | -58.82% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.92% | +0.87% | -11.34% | -71.51% |